ArticleClinical oral investigations2025
The potential of resolvin D2 loaded hydroxyapatite/mineral trioxide aggregate electrospun membranes to downregulate Interleukin 1 beta and tumor necrosis factor alpha in human dental pulp stem cells and macrophages co-cultures.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Immunomodulatory and angiogenic strategies in vital pulp therapy: a systematic review of scaffold-based, scaffold-free, and cell-laden interventions.Clinical oral investigations · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo develop electrospun polycaprolactone (PCL) membranes incorporating Hydroxyapatite/Mineral Trioxide Aggregate (HAp/MTA) loaded with Resolvin D2 (RvD2) and evaluate its anti-inflammatory potential.
methodElectrospun membranes were fabricated by blending PCL with 10 wt.% HAp/10 wt.% MTA loaded with or without 0.1% RvD2 and were characterized using Field Emission Scanning Electron Microscopy (FE-SEM), energy-dispersive X-ray (EDX) spectroscopy, Raman spectroscopy, contact angle measurements, and RvD2 release.
resultsThe field emission scanning microscopy (FE-SEM) showed uniform nanofibers with an average fiber diameter ranging from 300 to 600 nm. Energy-dispersive X-ray (EDX) analysis and Raman spectroscopy confirmed the presence of HAp and MTA in the PCL membranes. The drug release profile displayed a rapid release of RvD2 initially, followed by a sustained release. XTT assay demonstrated the cytocompatibility of the membranes towards the THP-1-derived M1 macrophages and human dental pulp stem cells (hDPSCs) co-cultures activated with LPS. The FE-SEM studies proved the favorable cell adhesion behaviour although the membranes being hydrophobic. Cytokine levels in the culture supernatants retrieved from the co-culture treated membranes showed that, of all the membranes, RvD2 incorporated PCLHAp/MTA membranes demonstrated reduced IL-1β and TNF-α production.
conclusionsRvD2 incorporated PCLHAp/MTA membranes demonstrated reduced IL-1β and TNF-α production asserting its anti-inflammotory potential. CLINICAL SIGNIFICANCE: This research highlights the immunomodulatory effect of RvD2-loaded PCLHAp/MTA electrospun membranes in reducing inflammation of the dental pulp. This novel method has the potential to transform the treatment of dental pulp inflammation resulting from caries or injury.
Indexed as
Identifiers
40542955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.